 BD Becton, Dickinson and Company NYSE: BDX, a leading global medical technology company, today announced that it received approval for a pre-market approval PMA supplement from the U.S. Food and Drug Administration FDA for an expanded version of its BD OnclarityTM HPV Assay. The PMA supplement includes the expansion for genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 3358, 353968, and 565966 genotypes making the BD OnclarityTM HPV Assay the only FDA-approved assay to individually identify and report these genotype results. 